Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Yale Cancer Center, Yale University, Stony Brook Medicine, Centre Hospitalier Universitaire Amiens-Picardie, Klinikum Braunschweig, Universitair Ziekenhuis Leuven, Centre Hospitalier Universitaire de Tours, Huntsman Cancer Institute, Montefiore Medical Center, University of Oxford, Oxford University Hospitals NHS Trust, Roswell Park Comprehensive Cancer Center, Pfizer (United States), Cleveland Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W3032782811